There is no single best medicine for autoimmune disease because more than 80 different autoimmune conditions exist, each affecting the body differently. The right treatment depends on which disease you have, how severe it is, and how your body responds. That said, the medications used across most autoimmune diseases fall into a clear hierarchy, starting with broad inflammation control and moving toward highly targeted therapies when simpler options fall short.
How Autoimmune Medications Are Organized
Doctors treat autoimmune diseases using a stepwise approach. The main categories, from broadest to most targeted, are: anti-inflammatory painkillers (NSAIDs), corticosteroids, disease-modifying drugs (DMARDs), and biologics. Each level works differently, and most people end up on some combination rather than a single pill.
NSAIDs and corticosteroids handle pain and inflammation but don’t slow the underlying disease. DMARDs go further by actually reducing the tissue and organ damage that chronic inflammation causes over time. Biologics, the newest class, block specific molecules in the immune system that drive the attack on your own body. The trend in treatment over the past two decades has been toward using targeted therapies earlier, rather than waiting until damage accumulates.
The Starting Point for Most Conditions
For rheumatoid arthritis, the most common serious autoimmune joint disease, methotrexate remains the first drug doctors reach for. It has decades of evidence behind it, a good response rate, an acceptable side effect profile, and relatively low cost. European guidelines recommend it as part of every initial treatment plan, typically escalated up to about 25 mg once a week alongside folic acid supplements to reduce side effects like nausea and mouth sores.
For lupus, a different drug takes center stage. Hydroxychloroquine (originally developed as an antimalarial) is recommended for virtually all lupus patients, dosed at about 5 mg per kilogram of body weight per day. It reduces flares, protects organs, and improves long-term survival. Eye exams are needed periodically because the drug can, rarely, affect the retina over many years of use.
When someone with rheumatoid arthritis can’t tolerate methotrexate, two common alternatives are sulfasalazine (typically 3,000 mg per day) and leflunomide (20 mg per day). These are in the same broad drug class and can also be combined with methotrexate if a single drug isn’t enough.
Corticosteroids: Powerful but Short-Term
Corticosteroids like prednisone can dramatically reduce inflammation within days, which makes them invaluable during flares or while waiting for slower-acting drugs to kick in. But they come with serious long-term costs: bone thinning, weight gain, high blood sugar, mood changes, and increased infection risk. Current guidelines urge doctors to use them for no more than three months when starting or switching a disease-modifying drug, with a tapering plan built in from day one. Some specialists prefer a single injection rather than weeks of oral pills to minimize exposure.
Biologics and When They’re Used
Biologics are lab-engineered proteins that block specific parts of the immune system. The first generation targeted a molecule called TNF, which fuels inflammation in rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. These drugs transformed outcomes for people who weren’t getting better on traditional medications.
Biologics are typically reserved for people who haven’t responded well to at least one conventional disease-modifying drug. They’re given by injection or infusion, often every one to four weeks depending on the specific drug. Because they suppress parts of the immune system precisely, they carry a higher risk of certain infections, particularly tuberculosis reactivation, so screening happens before you start.
One development that has made biologics more accessible is the arrival of biosimilars. These are near-identical copies of original biologic drugs, approved by the FDA only after demonstrating no clinically meaningful differences in safety or effectiveness. They’re given the same way, at the same strength, with the same expected side effects. Biosimilars create more competition in the market, which can lower costs, though actual savings vary by insurance plan and pharmacy.
JAK Inhibitors: Targeted but Carrying Warnings
A newer class of oral medications called JAK inhibitors works by blocking signals inside immune cells rather than targeting molecules outside the cell. They’re taken as pills rather than injections, which many people prefer. However, the FDA has placed serious safety warnings on this entire class after a large clinical trial found increased risks of heart attack, stroke, blood clots, cancer, and death compared to TNF-blocking biologics.
In that trial, patients on the JAK inhibitor had roughly 33% higher risk of major cardiovascular events and 48% higher risk of cancers (excluding common skin cancers) compared to those on a TNF blocker. Lymphoma and lung cancer rates were also elevated. Because of these findings, the FDA now requires that JAK inhibitors be reserved for patients who have already tried and failed, or can’t tolerate, at least one TNF-blocking biologic. Your doctor will weigh your individual cardiovascular and cancer risk factors before considering this option.
Newer Approvals Expanding Options
The landscape continues to shift as new drugs reach the market. In 2025 alone, the FDA approved several medications for autoimmune-related conditions. Imaavy was approved for generalized myasthenia gravis, a disease where the immune system attacks the connection between nerves and muscles. Wayrilz was approved for immune thrombocytopenia, a condition where the body destroys its own platelets, in patients who haven’t responded well to standard treatments. Rhapsido was approved for chronic spontaneous urticaria (persistent hives) in adults who don’t get relief from antihistamines alone.
A topical option also emerged: a cream approved for moderate-to-severe chronic hand eczema when corticosteroid creams aren’t working or aren’t advisable. These approvals reflect a broader trend toward more condition-specific, mechanism-specific treatments rather than broad immunosuppression.
What Long-Term Treatment Looks Like
Most autoimmune diseases require ongoing medication, often for life. That means regular monitoring. If you’re on disease-modifying drugs or biologics, expect periodic blood tests to check liver function, blood cell counts, and kidney markers. The frequency depends on the drug: some require blood work every few weeks early on, tapering to every few months once your levels stabilize.
Infection risk is a constant consideration with any immune-suppressing therapy. You’ll likely be advised to stay current on vaccinations (ideally before starting treatment, since live vaccines can be dangerous on immunosuppression), and to report fevers or signs of infection promptly. Bone density monitoring may also be recommended if you’ve used corticosteroids for any extended period.
Why Treatment Varies So Much Between People
Two people with the same autoimmune disease can end up on completely different medications. Part of this comes down to disease severity, organ involvement, and other health conditions. Someone with rheumatoid arthritis and a history of heart disease, for example, would likely be steered away from JAK inhibitors. Someone with lupus affecting the kidneys needs more aggressive immunosuppression than someone with joint symptoms alone.
Researchers are also working on using blood-based biomarkers to predict which patients will respond to which drugs before starting treatment, rather than relying on trial and error. In lupus, for instance, certain antibody levels in the blood have shown promise in predicting who will benefit from specific biologic therapies. This kind of precision is still emerging, but it points toward a future where the “best” medicine for your autoimmune disease is matched to your biology, not just your diagnosis.
For now, the most effective approach remains a close partnership with a specialist, typically a rheumatologist, dermatologist, or gastroenterologist depending on your condition, who can adjust your treatment as your disease evolves over time.